Drug Profile
RG 7167
Alternative Names: CH4987655; CIF - Chugai; R7167; RG7167; RO-4987655Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Roche
- Class 3-ring heterocyclic compounds; Antineoplastics; Benzamides; Small molecules
- Mechanism of Action Cytochrome inhibitors; Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Dec 2014 Roche completes a phase I trial for Solid tumours (late-stage disease, monotherapy) in France, Germany, Netherlands, Spain and the UK (NCT00817518)
- 24 Jul 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in France (PO)
- 24 Jul 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in Germany (PO)